Peptide

Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences

Retrieved on: 
Monday, April 8, 2024
Farmer, Growth, Agriculture, Vegetable, O'Shea, Mitsui, Flagship Pioneering, Food, Flagship, Peptide, Citrus, Management

CAMBRIDGE, Mass., April 8, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Invaio Sciences, a bioplatform company accelerating the leap to nature-positive agriculture, today announced that Amy O'Shea has joined Flagship Pioneering as CEO-Partner and Invaio as Chief Executive Officer and Board Director.

Key Points: 
  • O'Shea is a Seasoned Global Executive with more than 20 Years' Experience across the Agriculture, Food and Pharmaceutical Industries
    CAMBRIDGE, Mass., April 8, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Invaio Sciences, a bioplatform company accelerating the leap to nature-positive agriculture, today announced that Amy O'Shea has joined Flagship Pioneering as CEO-Partner and Invaio as Chief Executive Officer and Board Director.
  • O'Shea is a seasoned global executive with more than 20 years' experience across the agriculture, food, and pharmaceutical industries.
  • "That's just the start as Invaio pioneers a new approach in agriculture by combining novel active ingredients and delivery systems.
  • "I have been impressed with Invaio's technologies and capabilities and am excited to join the team," said Amy O'Shea, Flagship Pioneering CEO-Partner and Invaio CEO and Board Director.

IdeeLab Joins the Ginkgo Technology Network to Provide Agriculture Companies in Brazil with End-to-End Product Development & Manufacturing Service

Retrieved on: 
Monday, April 8, 2024
Agriculture, Partnership, SVP, DNA, AI, Biotechnology, Protein, Fermentation, Genetically modified organism, Corporation, Peptide, Fine chemical

PIRACICABA, Brazil, April 8, 2024 /PRNewswire/ -- IdeeLab Biotechnology, a Brazilian company aiming to develop innovations and biological solutions for agriculture, today announced that is has entered into an agreement with Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, to join the Ginkgo Technology Network.

Key Points: 
  • The Ginkgo Technology Network is a groundbreaking global ecosystem of cutting-edge technology partners dedicated to driving innovation in customer R&D programs.
  • Ginkgo plans to integrate the technological capabilities of its network partners to provide customers with more robust end-to-end solutions to drive successful R&D outcomes across biological end markets.
  • IdeeLab is leading sustainable agriculture biological products development in Brazil by developing new technologies on behalf of customers for the crop input market.
  • Anna Marie Wagner, Ginkgo's SVP, Head of AI and Corporate Development: "IdeeLab has been inspiring a new era in Brazilian agriculture and we're thrilled to welcome them to the Ginkgo Technology Network!

Sanara MedTech Inc. Announces Fourth Quarter and Full Year 2023 Results

Retrieved on: 
Monday, March 25, 2024
Tax, Growth, Tufts University, Patient, Extracellular matrix, Classification, Sale, Acquisition, Nature, Adjustment, SMTI, Infection, Depreciation, GAAP, Peptide

Zach Fleming, Sanara's CEO, stated, “During 2023, the Sanara team achieved several key strategic and operational milestones that position the Company for continued strong growth in 2024.

Key Points: 
  • Zach Fleming, Sanara's CEO, stated, “During 2023, the Sanara team achieved several key strategic and operational milestones that position the Company for continued strong growth in 2024.
  • The Company’s products were contracted or approved to be sold in more than 3,000 hospitals/ambulatory surgery centers as of December 31, 2023.
  • In October 2023, Sanara recorded its first sale of ALLOCYTE® Plus, a human cell and tissue-based product.
  • In November 2023, Sanara announced the publication of a retrospective study involving 5,335 patients.

Carmell to Host Investor Webinar, “Unveiling the Secretome: On the Eve of Product Launch” Featuring Key Opinion Leaders in the Medical Aesthetics Field

Retrieved on: 
Monday, March 18, 2024
Harvard Medical School, Worldwide, Research, Doctor of Philosophy, Protein, Regius Professor, Skin, Secretome, Safety, FACS, FRCS, BLA, Peptide, Vaccine

Carmell's Secretome technology delivers 1000+ growth factors, proteins and peptides extracted from allogeneic human platelets in a twelve-month shelf-stable and biologically active formulation.

Key Points: 
  • Carmell's Secretome technology delivers 1000+ growth factors, proteins and peptides extracted from allogeneic human platelets in a twelve-month shelf-stable and biologically active formulation.
  • Carmell’s technology was previously being developed as a BLA and has Phase 2 human clinical data supporting safety and efficacy.
  • In comparison, other aesthetic products feature 1-2 synthetic proteins with sparse evidence of clinical efficacy.
  • Carmell aims to launch a limited-edition product this month followed by 9 other skincare products over the summer 2024.

The American Dream: Doctors Unite to Educate About Proactive Health on "The World Wellness Show"

Retrieved on: 
Thursday, March 14, 2024
Health, Dizziness, Medicine, Education, Knowledge, ALL, Social media, Interview, DSM-IV codes, Life expectancy, Chiropractic, Host, Neuropsychology, Peptide

GAINESVILLE, Fla., March 14, 2024 (GLOBE NEWSWIRE) -- The World Wellness Show expands collaborative movement towards proactive health to 137 countries with the help of top wellness experts.

Key Points: 
  • GAINESVILLE, Fla., March 14, 2024 (GLOBE NEWSWIRE) -- The World Wellness Show expands collaborative movement towards proactive health to 137 countries with the help of top wellness experts.
  • Doctors wanting to share "their messages" globally and create personalized content for their clinic's social media and websites can schedule their interview now at: www.TheWorldWellnessShow.com .
  • Trish Gleason, Host of the World Wellness Show, shared: “Together we can educate the world and spark a shift in wellcare from treatment to prevention.
  • Our goal is to spark a paradigm shift to how we perceive and prioritize health and move away from reactive treatments and towards proactive wellness practices.

ARECOR AND TRx BIOSCIENCES ESTABLISH RESEARCH COLLABORATION TO DEVELOP ORAL GLP-1 WITH ENHANCED BIOAVAILABILITY

Retrieved on: 
Tuesday, March 12, 2024
Absorption, Obesity, Diabetes, Human, Patient, Gastrointestinal tract, AREC, Semaglutide, Drug development, TRX, AIM, Peptide, Vaccine

Oral delivery of this class of drug is extremely challenging owing to the proteolytic nature of the digestive system which significantly reduces bioavailability.

Key Points: 
  • Oral delivery of this class of drug is extremely challenging owing to the proteolytic nature of the digestive system which significantly reduces bioavailability.
  • Using TRx Biosciences’ LipiCore™ oral delivery technology alongside Arecor’s formulation platform, Arestat™, the companies intend to jointly develop an oral GLP-1 receptor agonist product with enhanced physicochemical properties that can achieve higher oral bioavailability and stability.
  • Alongside TRx Biosciences and its expertise in targeted oral drug delivery, we have an opportunity to develop an enhanced oral GLP-1 receptor agonist product.
  • Success with semaglutide may offer a path to multiple oral peptide products with enhanced absorption and efficacy.”
    The collaboration provides scope for expansion, following the initial oral GLP-1 receptor agonist programme, to develop further oral peptide products.

Nimble Therapeutics Expands its Drug Discovery Capabilities to Advance Pipeline to the Clinic

Retrieved on: 
Wednesday, April 3, 2024
Oncology, Health, Infectious Diseases, Radiology, Pharmaceutical, Biotechnology, Pfizer, De Montfort University, Drug discovery, Yale University, BU, Harvard University, Patient, Flavell, Immunology, Merck, Head, Wetzler, Merck & Co., IND, Rhône-Poulenc, Therapy, CSO, American Chemical Society, Medicinal chemistry, Peptide, Pharmaceutical industry

In addition to the new site, Nimble also announced the appointment of two senior leaders to spearhead the drug discovery efforts and catalyze the build out of the Philadelphia site and team.

Key Points: 
  • In addition to the new site, Nimble also announced the appointment of two senior leaders to spearhead the drug discovery efforts and catalyze the build out of the Philadelphia site and team.
  • Shelley Allen will join as Head of Drug Discovery and will lead the advanced optimization and characterization of clinical candidate peptides and their progression into the clinic.
  • Munir Mosaheb will join as Head of Biology and will lead the pharmacological, immunological and translational aspects of Nimble’s drug discovery programs.
  • She joined Nimble from Think Bioscience where she was VP, Medicinal Chemistry, and responsible for establishing drug discovery teams and capabilities to develop their internal programs.

Longhorn Vaccines and Diagnostics Presents at World Vaccine Congress on Advantages of Single Peptide Vaccine for Broad Coverage of Human and Avian Influenza Viruses

Retrieved on: 
Tuesday, April 2, 2024
Health, Infectious Diseases, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, Congress, Isotype, Influenza, Group 1, Public, Vaccine, Epitope, ELISA, Mouse, Immunoglobulin G, IND, Immunity, InvivoGen, Poster, Peptide

Results from the poster show that LHNVD-110 generated broadly reactive antibodies to human and highly pathogenic avian influenza viruses while neutralizing seasonal and pandemic influenza strains.

Key Points: 
  • Results from the poster show that LHNVD-110 generated broadly reactive antibodies to human and highly pathogenic avian influenza viruses while neutralizing seasonal and pandemic influenza strains.
  • This data mirrors previous studies with LHNVD-105, a dual peptide vaccines containing the same epitopes.
  • Using a single peptide provides a more cost-effective and easily scalable approach to such a universal influenza vaccine.
  • That is why using peptide-based vaccines with broad strain coverage may offer useful strategies towards preventing influenza, no matter the strain.

ReAlta Life Sciences Announces New Research Collaboration with the National Institute of Allergy and Infectious Diseases to Evaluate RLS-0071 as a Medical Countermeasure for Acute Radiation Syndrome

Retrieved on: 
Thursday, March 28, 2024
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Other Science, Science, Radiation, Acute radiation syndrome, Attack, ARS, Inflammation, Education, Chronic obstructive pulmonary disease, RNCP, USUHS, Virus, IND, European Medicines Agency, Outline of health sciences, Nausea, Accident, Hypoxia (medical), NIAID, Defense Threat Reduction Agency, AFRRI, HIE, Vaccine, Collection, Vomiting, Food, FDA, Defense, Infection, Peptide, Pharmaceutical industry

“We are very pleased to partner with NIAID and AFRRI to evaluate ReAlta’s lead drug candidate, RLS-0071, as a radiation countermeasure for GI-ARS,” says Dr. Ulrich Thienel, Chief Executive Officer of ReAlta.

Key Points: 
  • “We are very pleased to partner with NIAID and AFRRI to evaluate ReAlta’s lead drug candidate, RLS-0071, as a radiation countermeasure for GI-ARS,” says Dr. Ulrich Thienel, Chief Executive Officer of ReAlta.
  • AFRRI is unique and powerful radiobiological research institute, with six decades of active, robust, and outstanding support to the U.S. Department of Defense through research, reach-back, and education.
  • It is the only U. S. Department of Defense medical R&D facility dedicated solely to nuclear and radiological defense.
  • ReAlta Life Sciences, Inc. is a mid-stage clinical biotech company dedicated to saving lives by rebalancing the inflammatory response to address life threatening acute inflammatory and rare diseases.

Synthetic Hormones Market Research Report 2024: Development of New Delivery Systems and Formulations, & Demand for HRT - Global Analysis and Forecast, 2023-2033 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 27, 2024
Pharmaceutical, Health, Other Health, Hospital, Peptide, Birth, Hypothyroidism, Biotechnology, Prevalence, Growth, Human body, Incidence, Insulin, Diabetes, Patient, Conditional sentence, Research, Menopause, World Health Organization, Investment, Skin, Hormone replacement therapy, Safety, HRT, WHO, Region, Administration, Ageing, Pharmaceutical industry

The development of new delivery systems and formulations that enhance patient compliance and reduce side effects further fuels the market growth.

Key Points: 
  • The development of new delivery systems and formulations that enhance patient compliance and reduce side effects further fuels the market growth.
  • Overall, the synthetic hormones market is expected to continue growing, driven by the need for effective treatments for hormonal disorders and the ongoing research and development in this field.
  • The increasing occurrence of hormonal disorders, including hypothyroidism, diabetes, and imbalances, plays a crucial role in propelling the synthetic hormones market.
  • The hospital pharmacies segment accounted for the largest share of the global synthetic hormones market (by end user) in 2022.